Baolingbao Biology Co Ltd Asset Resilience Ratio
Baolingbao Biology Co Ltd asset resilience ratio. Baolingbao Biology Co Ltd (002286) has an Asset Resilience Ratio of 0.07% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Baolingbao Biology Co Ltd to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Baolingbao Biology Co Ltd (2013–2025)
Asset resilience ratio of Baolingbao Biology Co Ltd from 2013 to 2025. This chart shows how Baolingbao Biology Co Ltd's Asset Resilience Ratio has changed over time. Read debt load of Baolingbao Biology Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Baolingbao Biology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Baolingbao Biology Co Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.00 Million | 0.07% |
| Total Liquid Assets | CN¥2.00 Million | 0.07% |
Asset Resilience Insights
- Limited Liquidity: Baolingbao Biology Co Ltd maintains only 0.07% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Baolingbao Biology Co Ltd Industry Peers by Asset Resilience Ratio
Compare Baolingbao Biology Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 36.07% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 49.53% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Hyundai Bioscience Co. Ltd
KQ:048410 |
Biotechnology | 18.85% |
|
AbClon Inc
KQ:174900 |
Biotechnology | 9.30% |
|
Altimmune Inc
NASDAQ:ALT |
Biotechnology | 82.06% |
Baolingbao Biology Co Ltd Asset Resilience Ratio by Year (2013–2025)
Baolingbao Biology Co Ltd asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Baolingbao Biology Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.10% | CN¥2.80 Million ≈ $409.73K |
CN¥2.78 Billion ≈ $407.01 Million |
+0.87pp |
| 2023-12-31 | -0.77% | CN¥-20.42 Million ≈ $-2.99 Million |
CN¥2.66 Billion ≈ $389.08 Million |
-4.29pp |
| 2021-12-31 | 3.52% | CN¥106.67 Million ≈ $15.61 Million |
CN¥3.03 Billion ≈ $443.24 Million |
+3.73pp |
| 2020-12-31 | -0.21% | CN¥-5.48 Million ≈ $-802.34K |
CN¥2.62 Billion ≈ $382.76 Million |
+0.09pp |
| 2019-12-31 | -0.30% | CN¥-7.62 Million ≈ $-1.12 Million |
CN¥2.52 Billion ≈ $368.57 Million |
+0.10pp |
| 2018-12-31 | -0.41% | CN¥-10.51 Million ≈ $-1.54 Million |
CN¥2.58 Billion ≈ $377.43 Million |
-0.29pp |
| 2017-12-31 | -0.12% | CN¥-2.44 Million ≈ $-357.60K |
CN¥2.11 Billion ≈ $308.31 Million |
0.00pp |
| 2016-12-31 | -0.11% | CN¥-2.15 Million ≈ $-314.40K |
CN¥1.93 Billion ≈ $282.65 Million |
-0.02pp |
| 2015-12-31 | -0.09% | CN¥-1.81 Million ≈ $-265.48K |
CN¥1.91 Billion ≈ $280.01 Million |
+0.01pp |
| 2014-12-31 | -0.11% | CN¥-1.91 Million ≈ $-279.19K |
CN¥1.77 Billion ≈ $258.44 Million |
+0.01pp |
| 2013-12-31 | -0.12% | CN¥-2.00 Million ≈ $-292.89K |
CN¥1.68 Billion ≈ $245.28 Million |
-- |
About Baolingbao Biology Co Ltd
Baolingbao Biology Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and sale of functional sugar in China and internationally. The company offers prebiotics, including galacto-oligosaccharides, isomaltooligosaccharides, fructooligosaccharides, and xylooligosaccharides; sugar alcohols and sources, such as erythritol, trehalose, crystallized fructose, a… Read more